Get started
Author

Trevor S. Anderson

Observed names: Anderson, Trevor S., Trevor S Anderson
ORCID: 0000-0001-6935-8164
Observed ORCID: 0000-0001-6935-8164
OpenAlex ID: A5073700210
Dendritic cell vaccine therapy for colorectal cancer
2020 · Amanda L. Wooster, Lydia H. Girgis, et al. · Pharmacological Research · 48
Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity
2022 · Trevor S. Anderson, Amanda L. Wooster, et al. · Seminars in Cancer Biology · 32
Listeria-based vaccination against the pericyte antigen RGS5 elicits anti-vascular effects and colon cancer protection
2023 · Trevor S. Anderson, Amanda L. McCormick, et al. · OncoImmunology · 16
Targeting the pericyte antigen DLK1 with an alpha type-1 polarized dendritic cell vaccine results in tumor vascular modulation and protection against colon cancer progression
2023 · Amanda L. McCormick, Trevor S. Anderson, et al. · Frontiers in Immunology · 9
PDF
Antibody-drug conjugates: an evolving approach for melanoma treatment
2020 · Trevor S. Anderson, Amanda L. Wooster, et al. · Melanoma Research · 8
Expression and characterization of soluble epitope-defined major histocompatibility complex (MHC) from stable eukaryotic cell lines
2018 · Amanda L. Wooster, Trevor S. Anderson, et al. · Journal of Immunological Methods · 8
Modeling antibody drug conjugate potential using a granzyme B antibody fusion protein
2024 · Trevor S. Anderson, Amanda L. McCormick, et al. · BMC Biology · 4
PDF
A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
2025 · Izuchukwu F. Okpalanwaka, Elizabeth A. Daugherity, et al. · Molecular Cancer Therapeutics · 3
Supplementary Figure 4 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
2025 · Izuchukwu F. Okpalanwaka, Elizabeth A. Daugherity, et al.
Supplementary Figure 3 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
2025 · Izuchukwu F. Okpalanwaka, Elizabeth A. Daugherity, et al.
Supplementary Figure 6 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
2025 · Izuchukwu F. Okpalanwaka, Elizabeth A. Daugherity, et al.
Data from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
2025 · Izuchukwu F. Okpalanwaka, Elizabeth A. Daugherity, et al.
Supplementary Table 2 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
2025 · Izuchukwu F. Okpalanwaka, Elizabeth A. Daugherity, et al.
Supplementary Figure 8 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
2025 · Izuchukwu F. Okpalanwaka, Elizabeth A. Daugherity, et al.
Supplementary Figure 1 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
2025 · Izuchukwu F. Okpalanwaka, Elizabeth A. Daugherity, et al.
Supplementary Figure 9 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
2025 · Izuchukwu F. Okpalanwaka, Elizabeth A. Daugherity, et al.
Supplementary Figure 2 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
2025 · Izuchukwu F. Okpalanwaka, Elizabeth A. Daugherity, et al.
Supplementary Figure 7 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
2025 · Izuchukwu F. Okpalanwaka, Elizabeth A. Daugherity, et al.
Supplementary Table 1 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
2025 · Izuchukwu F. Okpalanwaka, Elizabeth A. Daugherity, et al.
Supplementary Figure 5 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
2025 · Izuchukwu F. Okpalanwaka, Elizabeth A. Daugherity, et al.
Abstract B010: A PD-L1 x CD3 bispecific antibody enhances the anti-tumor efficacy of regorafenib in pre-clinical colon cancer models
2024 · Izuchukwu F Okpalanwaka, Elizabeth A Daugherity, et al. · Cancer Immunology Research
Abstract A68: Listeria monocytogenes-based vaccines to mediate targeted ablation of the tumor-associated vasculature in colorectal cancer
2022 · Trevor S Anderson, Amanda L Wooster, et al. · Cancer Immunology Research
Abstract A43: Analysis of the effects of therapeutic vaccination with tumor vascular-primed dendritic cells in a mouse model of colon cancer
2022 · Amanda L Wooster, Trevor S Anderson, et al. · Cancer Immunology Research
Works count: 27
Citation count: 128
H-index: 6
I10-index: 3
Year
Topic
Type